The Pharmacy Times® IVIG Resource Center is a comprehensive resource for clinical news and expert insights on the use of intravenous immunoglobulin, a product comprised of antibodies administered intravenously.
February 22nd 2023
Autoimmune diseases are often chronic conditions that can evolve, so minimizing damage and progression is typically the mainstay of treatment.
January 6th 2023
Intravenous Immunoglobulin May Improve Severe OCD in ChildrenDecember 19th 2022
Treatment observably eased obsessive-compulsive disorder symptom severity in young patients, however, symptoms still caused students to be absent from school at least 2 days every month.
Addition of Venetoclax to Richter Syndrome Treatment Regimen Achieves Complete Remission at 3 Months Post alloSCTDecember 12th 2022
Although patients with Richter syndrome often experience poor outcomes, there are many new treatment strategies that have demonstrated a durable response.
IVIG, Steroids for Multisystem Inflammatory Syndrome in Children Have Varying OutcomesNovember 16th 2022
Despite an apparent benefit of intravenous immunoglobulin (IVIG) on early discharge, the likelihood of needing second-line treatment was 3 times higher in patients who initiated treatment with IVIG alone.
Broad Spectrum of IVIG Targets, Non-Specificity Could Be Key to Efficacy in Various DiseasesNovember 11th 2022
Intravenous immunoglobulin is used for several autoimmune and inflammatory conditions, although researchers have not fully understood its specific mechanisms.
Clinical Overview: Teprotumumab for Thyroid Eye DiseaseNovember 3rd 2022
Teprotumumab is the first fully human IgG1 monoclonal antibody approved by the FDA for the treatment of thyroid eye disease at its source not just reducing the symptoms.
Options for Immunoglobulin Administration Allow for Personalized Treatment of Chronic Inflammatory Demyelinating PolyneuropathySeptember 19th 2022
Although there is no “best” way to determine which route of administration is best, health care providers are optimally positioned to educate patients and help them make the best decision.
Intravenous Immunoglobulin May Accelerate Platelet Count Stabilization, Recovery in Obinutuzumab-Related ThrombocytopeniaSeptember 6th 2022
Complete recovery of platelet counts after obinutuzumab-based therapy was found to be associated with, or accelerated by, intravenous immunoglobulin.
Effective Treatment for Some Patients with Arndt-Gottron Syndrome Can Be Achieved With IVIGSeptember 1st 2022
Though there is no well-defined therapeutic approach to the treatment of Arndt-Gottron syndrome, intravenous immunoglobulins have been documented as a well-tolerated treatment in some cases.
Plasmapheresis is Viable Treatment Option for Patients with Hashimoto’s Encephalopathy Nonresponsive to SteroidsAugust 9th 2022
Researchers recommend having a low clinical threshold for the diagnosis of Hashimoto’s encephalopathy in patients who reveal no apparent cause for their altered mental status, given the heterogenous nature of the condition’s presentation.
Study: Metronidazole Desensitization Effectively Treats Patients with Hypersensitivity ReactionsAugust 1st 2022
Patients with past medical histories of immunoglobulin E-mediated hypersensitivity reactions to metronidazole and other antimicrobial agents may receive safe and effective treatment using desensitization protocols.
Daily Medication Pearl: Privigen Immune Globulin Intravenous (Human)July 22nd 2022
Privigen is indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura in patients 15 years of age and older, chronic inflammatory demyelinating polyneuropathy in adults.
Patients with Suspicion of Systemic Disease Require Ongoing Follow-Up for DiagnosisJuly 14th 2022
A recent case report detailing multiple procedures and inconclusive biopsies underwent by a patient with unusual presentation of immunoglobulin G4-related disease before conclusive diagnosis emphasizes the importance of follow-up with patients with suspicion of systemic disease.
Investigators Report Series of Substates that Reprogram IgG to 1-Step Synthesis of gsADCsJune 20th 2022
Glycosite-specific antibody‒drug conjugates (gsADCs), harnessing Asn297 N-glycan of IgG Fc as the conjugation site for drug payloads, usually require multi-step glycoengineering with 2 or more enzymes, which limits the substrate diversification and complicates the preparation process.
Drug Sequestration in the Management of Patients with Extracorporeal Membrane Oxygenation SupportJune 8th 2022
Dosing recommendations for patients requiring ECMO support are unlikely to be supported by high-quality evidence, but are usually extrapolated from the physicochemical characteristics of individual drugs in conjunction with data from pharmacokinetic studies and case reports.